On 15 May 2026, Roche subsidiary Genentech announced that the FDA has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC) who have circulating tumour DNA molecular residual disease (ctDNA MRD) after cystectomy, as identified by a specified MRD assay.
This is the eleventh indication approved for Tecentriq® in the US since 2016, with the drug’s approved indications also including non-small cell lung cancer, hepatocellular carcinoma and melanoma. Tecentriq Hybreza®, the subcutaneously administered form of the drug, was approved in the US in September 2024.
No atezolizumab biosimilars have been approved to date.